Gastrointestinal stromal tumour (GIST)

Indication for Sunitinib

Population group: Suitable for both men and women, only adults (18 years old or older)

Sunitinib is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.

For this indication, competent medicine agencies globally authorize below treatments:

50 mg once daily

Route of admnistration


Defined daily dose

50 - 50 mg

Dosage regimen

From 50 To 50 mg once every day for 28 day(s)

Detailed description

The recommended dose of sunitinib is 50 mg taken orally once daily, for 4 consecutive weeks, followed by a 2-week rest period (Schedule 4/2) to comprise a complete cycle of 6 weeks.

Dosage considerations

It may be taken with or without food.

Active ingredient

Sunitinib inhibits multiple RTKs that are implicated in tumour growth, neoangiogenesis, and metastatic progression of cancer.

Read more about Sunitinib

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner